Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
The Review of Scientific Instruments
|
March 3, 2016
Operation and commissioning of IFMIF (International Fusion Materials Irradiation Facility) LIPAc injector
Y Okumura, R Gobin, J Knaster, et al.
ESMO Open
|
December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
G Lo Russo, F Sgambelluri, A Prelaj, et al.
Seminars in Cancer Biology
|
July 11, 2018
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
F Klauschen, K-R Müller, A Binder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
C B Westphalen, L Boscolo Bielo, P Aftimos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2025
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
L Provenzano, M V Dieci, G Curigliano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 13, 2014
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R Salgado, C Denkert, S Demaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P Tarantino, G Viale, M F Press, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
NPJ Precision Oncology
|
April 10, 2026
The role of the molecular tumor board: learnings from the ROME trial
P Marchetti, G Curigliano, C B Westphalen, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
The Review of Scientific Instruments
|
March 3, 2016
Operation and commissioning of IFMIF (International Fusion Materials Irradiation Facility) LIPAc injector
Y Okumura, R Gobin, J Knaster, et al.
ESMO Open
|
December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
G Lo Russo, F Sgambelluri, A Prelaj, et al.
Seminars in Cancer Biology
|
July 11, 2018
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
F Klauschen, K-R Müller, A Binder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
C B Westphalen, L Boscolo Bielo, P Aftimos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2025
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
L Provenzano, M V Dieci, G Curigliano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 13, 2014
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R Salgado, C Denkert, S Demaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P Tarantino, G Viale, M F Press, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
NPJ Precision Oncology
|
April 10, 2026
The role of the molecular tumor board: learnings from the ROME trial
P Marchetti, G Curigliano, C B Westphalen, et al.
Page
of 11